Skip to main content Back to Top
Advertisement

1/22/2020

Recombinant Zoster Vaccine (Shingrix)

Products Affected - Description

    • Shingrix, GlaxoSmithKline, 0.5 mL vial, 1 count, NDC 58160-0819-12
    • Shingrix, GlaxoSmithKline, 0.5 mL vial, 10 count, NDC 58160-0823-11

Reason for the Shortage

    • GlaxoSmithKline has Shingrix on shortage due to high demand for the product.

Available Products

    • There is insufficient supply for usual ordering

Estimated Resupply Dates

    • GlaxoSmithKline has Shingrix on allocation with regular releases.

Updated

Updated January 22, 2020 by Leslie Jensen, PharmD, Drug Information Specialist. Created May 17, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.